Key Points
Dec 11 (Reuters) - Patients on Eli Lilly's (LLY.N) weight-loss drug substantially regained weight after stopping treatment, according to a study published in journal JAMA on Monday.. The study showed that patients who were obese and without diabetes experienced a 14% weight regain, 52 weeks after switching to placebo from Lilly's tirzepatide...
Lilly's tirzepatide is sold under brand name Zepbound for weight loss and has been available as Mounjaro for type 2 diabetes...
The new weight-loss drugs belong to a class of treatments known as GLP-1 agonists, which was originally designed to treat type 2 diabetes and have been shown to reduce food cravings and cause the stomach to empty more slowly...
